IMMUNOTERAPIA ENDOVESCICALE CON INTERLEUCHINA-2 RICOMBINANTE (RIL-2) NEL CA. VESCICALE DI BASSO STADIO. STUDIO DI FASE IB

Translated title of the contribution: Intravesical immunotherapy with recombinant interleukin-2 (rIL-2) in low stage bladder cnacer. Study of IB phase

A. Tubaro, F. Velotti, A. Stoppacciaro, P. C. Bossola, G. Cusumano, F. Scapellato, P. Galassi, P. De Carli, V. Tonelli, A. Santoni, L. Ruco, A. Cancrini, L. Miano

Research output: Contribution to journalArticle

Abstract

Twenty-four patients (22 males and 2 females; age range 37-75 years, mean 58 years, median 63) with transitional cell carcinoma of the bladder (Ta-T1, N0, M0; G1-2) were entered into the study between September 1989 and July 1991. An induction course of 10 daily intravesical instillations was administered with the tumour in place using four different doses of recombinant interleukin-2 (rIL-2) ranging from 3 to 18 x 106 IU/day. Transurethral resection of the bladder tumour (TUR-BT) was carried out 10-14 days after the last rIL-2 dose. One month later, a first maintenance course (10 daily intravesical instillations of rIL-2) was started at the dose of 6 x 106 IU/day in all patients, and repeated every 4 months for one year. Objective clinical response to the induction course of rIL-2 was evaluated by ultrasound sonography and cystoscopy just before transurethral resection. Physical examination, laboratory tests and cystoscopy were carried out bimonthly throughout the study. No laboratory or clinical toxicity was observed in any patient. Partial regression of the primary tumour was observed in 5 out of 24 patients; 19 patients were considered as 'stable disease'; no tumour progression occurred. Twenty-four patients are evaluable for response with a follow-up ranging from 3 to 24 months (mean 12.5, median 11). Local tumour relapses were diagnosed in 6 out of 24 patients between 3 and 7 months (median 4) after TUR-BT; 18 patients remain with no evidence of disease. Regression of the primary tumour, observed in some patients, suggests an interesting biological and clinical activity of rIL-2 intravesical immunotherapy on bladder cancer. No definitive conclusions can yet be drawn on the effect of this treatment schedule on local tumour recurrence rate.

Original languageItalian
Pages (from-to)411-415
Number of pages5
JournalActa Urologica Italica
Volume6
Issue numberSUPPL. 6
Publication statusPublished - 1992

Fingerprint

Immunotherapy
Interleukin-2
Urinary Bladder
Urinary Bladder Neoplasms
Intravesical Administration
Neoplasms
Cystoscopy
Recurrence
Transitional Cell Carcinoma
Physical Examination
Ultrasonography
Appointments and Schedules
Maintenance

ASJC Scopus subject areas

  • Urology

Cite this

Tubaro, A., Velotti, F., Stoppacciaro, A., Bossola, P. C., Cusumano, G., Scapellato, F., ... Miano, L. (1992). IMMUNOTERAPIA ENDOVESCICALE CON INTERLEUCHINA-2 RICOMBINANTE (RIL-2) NEL CA. VESCICALE DI BASSO STADIO. STUDIO DI FASE IB. Acta Urologica Italica, 6(SUPPL. 6), 411-415.

IMMUNOTERAPIA ENDOVESCICALE CON INTERLEUCHINA-2 RICOMBINANTE (RIL-2) NEL CA. VESCICALE DI BASSO STADIO. STUDIO DI FASE IB. / Tubaro, A.; Velotti, F.; Stoppacciaro, A.; Bossola, P. C.; Cusumano, G.; Scapellato, F.; Galassi, P.; De Carli, P.; Tonelli, V.; Santoni, A.; Ruco, L.; Cancrini, A.; Miano, L.

In: Acta Urologica Italica, Vol. 6, No. SUPPL. 6, 1992, p. 411-415.

Research output: Contribution to journalArticle

Tubaro, A, Velotti, F, Stoppacciaro, A, Bossola, PC, Cusumano, G, Scapellato, F, Galassi, P, De Carli, P, Tonelli, V, Santoni, A, Ruco, L, Cancrini, A & Miano, L 1992, 'IMMUNOTERAPIA ENDOVESCICALE CON INTERLEUCHINA-2 RICOMBINANTE (RIL-2) NEL CA. VESCICALE DI BASSO STADIO. STUDIO DI FASE IB', Acta Urologica Italica, vol. 6, no. SUPPL. 6, pp. 411-415.
Tubaro A, Velotti F, Stoppacciaro A, Bossola PC, Cusumano G, Scapellato F et al. IMMUNOTERAPIA ENDOVESCICALE CON INTERLEUCHINA-2 RICOMBINANTE (RIL-2) NEL CA. VESCICALE DI BASSO STADIO. STUDIO DI FASE IB. Acta Urologica Italica. 1992;6(SUPPL. 6):411-415.
Tubaro, A. ; Velotti, F. ; Stoppacciaro, A. ; Bossola, P. C. ; Cusumano, G. ; Scapellato, F. ; Galassi, P. ; De Carli, P. ; Tonelli, V. ; Santoni, A. ; Ruco, L. ; Cancrini, A. ; Miano, L. / IMMUNOTERAPIA ENDOVESCICALE CON INTERLEUCHINA-2 RICOMBINANTE (RIL-2) NEL CA. VESCICALE DI BASSO STADIO. STUDIO DI FASE IB. In: Acta Urologica Italica. 1992 ; Vol. 6, No. SUPPL. 6. pp. 411-415.
@article{9c0f9ecd93a84aa2b50c9366176b89e3,
title = "IMMUNOTERAPIA ENDOVESCICALE CON INTERLEUCHINA-2 RICOMBINANTE (RIL-2) NEL CA. VESCICALE DI BASSO STADIO. STUDIO DI FASE IB",
abstract = "Twenty-four patients (22 males and 2 females; age range 37-75 years, mean 58 years, median 63) with transitional cell carcinoma of the bladder (Ta-T1, N0, M0; G1-2) were entered into the study between September 1989 and July 1991. An induction course of 10 daily intravesical instillations was administered with the tumour in place using four different doses of recombinant interleukin-2 (rIL-2) ranging from 3 to 18 x 106 IU/day. Transurethral resection of the bladder tumour (TUR-BT) was carried out 10-14 days after the last rIL-2 dose. One month later, a first maintenance course (10 daily intravesical instillations of rIL-2) was started at the dose of 6 x 106 IU/day in all patients, and repeated every 4 months for one year. Objective clinical response to the induction course of rIL-2 was evaluated by ultrasound sonography and cystoscopy just before transurethral resection. Physical examination, laboratory tests and cystoscopy were carried out bimonthly throughout the study. No laboratory or clinical toxicity was observed in any patient. Partial regression of the primary tumour was observed in 5 out of 24 patients; 19 patients were considered as 'stable disease'; no tumour progression occurred. Twenty-four patients are evaluable for response with a follow-up ranging from 3 to 24 months (mean 12.5, median 11). Local tumour relapses were diagnosed in 6 out of 24 patients between 3 and 7 months (median 4) after TUR-BT; 18 patients remain with no evidence of disease. Regression of the primary tumour, observed in some patients, suggests an interesting biological and clinical activity of rIL-2 intravesical immunotherapy on bladder cancer. No definitive conclusions can yet be drawn on the effect of this treatment schedule on local tumour recurrence rate.",
author = "A. Tubaro and F. Velotti and A. Stoppacciaro and Bossola, {P. C.} and G. Cusumano and F. Scapellato and P. Galassi and {De Carli}, P. and V. Tonelli and A. Santoni and L. Ruco and A. Cancrini and L. Miano",
year = "1992",
language = "Italian",
volume = "6",
pages = "411--415",
journal = "Acta Urologica Italica",
issn = "0394-2511",
publisher = "S. Karger AG",
number = "SUPPL. 6",

}

TY - JOUR

T1 - IMMUNOTERAPIA ENDOVESCICALE CON INTERLEUCHINA-2 RICOMBINANTE (RIL-2) NEL CA. VESCICALE DI BASSO STADIO. STUDIO DI FASE IB

AU - Tubaro, A.

AU - Velotti, F.

AU - Stoppacciaro, A.

AU - Bossola, P. C.

AU - Cusumano, G.

AU - Scapellato, F.

AU - Galassi, P.

AU - De Carli, P.

AU - Tonelli, V.

AU - Santoni, A.

AU - Ruco, L.

AU - Cancrini, A.

AU - Miano, L.

PY - 1992

Y1 - 1992

N2 - Twenty-four patients (22 males and 2 females; age range 37-75 years, mean 58 years, median 63) with transitional cell carcinoma of the bladder (Ta-T1, N0, M0; G1-2) were entered into the study between September 1989 and July 1991. An induction course of 10 daily intravesical instillations was administered with the tumour in place using four different doses of recombinant interleukin-2 (rIL-2) ranging from 3 to 18 x 106 IU/day. Transurethral resection of the bladder tumour (TUR-BT) was carried out 10-14 days after the last rIL-2 dose. One month later, a first maintenance course (10 daily intravesical instillations of rIL-2) was started at the dose of 6 x 106 IU/day in all patients, and repeated every 4 months for one year. Objective clinical response to the induction course of rIL-2 was evaluated by ultrasound sonography and cystoscopy just before transurethral resection. Physical examination, laboratory tests and cystoscopy were carried out bimonthly throughout the study. No laboratory or clinical toxicity was observed in any patient. Partial regression of the primary tumour was observed in 5 out of 24 patients; 19 patients were considered as 'stable disease'; no tumour progression occurred. Twenty-four patients are evaluable for response with a follow-up ranging from 3 to 24 months (mean 12.5, median 11). Local tumour relapses were diagnosed in 6 out of 24 patients between 3 and 7 months (median 4) after TUR-BT; 18 patients remain with no evidence of disease. Regression of the primary tumour, observed in some patients, suggests an interesting biological and clinical activity of rIL-2 intravesical immunotherapy on bladder cancer. No definitive conclusions can yet be drawn on the effect of this treatment schedule on local tumour recurrence rate.

AB - Twenty-four patients (22 males and 2 females; age range 37-75 years, mean 58 years, median 63) with transitional cell carcinoma of the bladder (Ta-T1, N0, M0; G1-2) were entered into the study between September 1989 and July 1991. An induction course of 10 daily intravesical instillations was administered with the tumour in place using four different doses of recombinant interleukin-2 (rIL-2) ranging from 3 to 18 x 106 IU/day. Transurethral resection of the bladder tumour (TUR-BT) was carried out 10-14 days after the last rIL-2 dose. One month later, a first maintenance course (10 daily intravesical instillations of rIL-2) was started at the dose of 6 x 106 IU/day in all patients, and repeated every 4 months for one year. Objective clinical response to the induction course of rIL-2 was evaluated by ultrasound sonography and cystoscopy just before transurethral resection. Physical examination, laboratory tests and cystoscopy were carried out bimonthly throughout the study. No laboratory or clinical toxicity was observed in any patient. Partial regression of the primary tumour was observed in 5 out of 24 patients; 19 patients were considered as 'stable disease'; no tumour progression occurred. Twenty-four patients are evaluable for response with a follow-up ranging from 3 to 24 months (mean 12.5, median 11). Local tumour relapses were diagnosed in 6 out of 24 patients between 3 and 7 months (median 4) after TUR-BT; 18 patients remain with no evidence of disease. Regression of the primary tumour, observed in some patients, suggests an interesting biological and clinical activity of rIL-2 intravesical immunotherapy on bladder cancer. No definitive conclusions can yet be drawn on the effect of this treatment schedule on local tumour recurrence rate.

UR - http://www.scopus.com/inward/record.url?scp=0026956709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026956709&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0026956709

VL - 6

SP - 411

EP - 415

JO - Acta Urologica Italica

JF - Acta Urologica Italica

SN - 0394-2511

IS - SUPPL. 6

ER -